Atamyo Therapeutics Submits CTA in Europe for Limb-Girdle Muscular Dystrophy Type 2C/R5 Gene Therapy
Atamyo has received $8.6 million in nondilutive financing from France 2030 for ATA-200's development.
Atamyo Therapeutics has submitted a clinical trial application (CTA) in Europe with the intention of evaluating ATA-200, an investigational adeno-associated virus (AAV) vector-based gene therapy, for the treatment of γ-sarcoglycan (SGCG)-related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).1
Pending clearance of the CTA, the company is planning to evaluate the gene therapy in a phase 1b clinical trial (EUCT 2023-506440-16-00). Atamyo expects that the multicenter, dose-escalation study may begin dosing patients in the first half of next year. In addition to announcing the CTA submission, Atamyo also noted that it has received $8.6 million in nondilutive financing from France 2030, a program operated by Bpifrance, for ATA-200's development.
“LGMD-R5 is the most rapidly progressive and debilitating form of LGMDs with onset of symptoms in early childhood, a loss of ambulation before adulthood, and frequent cardiac impairment,” Sophie Olivier, MD, the chief medical officer of Atamyo, said in a statement.1 “No curative treatment exists for this disease.”
ATA-200 is comprised of an AAV vector that delivers a functional copy of the SGCG gene. In the trial, the therapy will be administered intravenously. Atamyo stated that in preclinical mouse model research, the gene therapy was shown to be tolerated and able to correct for symptoms and disease biomarkers.
“ATA-200 incorporates a new promoter that enhances the liver and cardiac safety of gene therapy,” Isabelle Richard, PhD, the co-founder and chief scientific officer of Atamyo, added to the statement.1 “This first-in-class experimental treatment represents a new hope for the patients”.
This announcement follows a positive update from the company earlier this month regarding its most advanced program, ATA-100 (previously referred to as GNT0006), which
Atamyo also has several additional LGMD gene therapy programs in the preclinical stages of development.7 These include potential treatments for LGMD-R1/LGMD2A (calpainopathy), LGMD-R2/LGMD2B (dysferlinopathy), and LGMD-R3/LGMD2D (deficiency in α-sarcoglycans). The LGMD-R1/LGMD2A program is currently in IND-enabling studies.1
“We are thrilled to file this European Clinical trial and to receive such a strong public financing for the devastating LGMD2C/R5 disease” Stephane Degove, the co-founder and chief executive officer of Atamyo, added to the statement.1 “With the ongoing clinical trial in LGMD-R9, the initiation of the clinical program for LGMD-R5/2C confirms our unique capabilities in bringing to patients suffering from limb-girdle muscular dystrophies a new generation of safe and effective gene therapies.”
REFERENCES
1. ATA-200, AtamyoTherapeutics’ gene therapy to treat limb-girdle muscular dystrophy type 2C/R5, reaches key milestones with the filing of a clinical trial application in Europe and a non-dilutive financing from France 2030 program. News release. Atamyo Therapeutics. September 19, 2023. Accessed September 28, 2023. https://atamyo.com/press-releases/https-atamyo-com-wp-content-uploads-pr-sept-19-2023-ata-200-reaches-key-milestones-with-cta-in-europe-and-france2030-financing-pdf/
2. IND for ATA-100, a gene therapy for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA. News release. Atamyo Therapeutics. September 5, 2023. Accessed September 28, 2023. https://atamyo.com/press-releases/2023/ind-for-ata-100-a-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9-lgmd2i-r9-cleared-to-proceed-by-fda/
3. Atamyo Therapeutics announces first patient dosed with ATA-100 gene therapy in LGMD-R9 clinical trial. News Release. Atamyo Therapeutics. September 26, 2022. Accessed September 28, 2023.https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-patient-dosed-with-ata-100-gene-therapy-in-lgmd-r9-clinical-trial/
4. Atamyo Therapeutics obtains first regulatory authorization in Europe to initiate a clinical trial for ATA-100, its gene therapy to treat limb-girdle muscular dystrophy type 2I/R9. News release. Atamyo Therapeutics. December 6, 2021. Accessed September 28, 2023. https://atamyo.com/press-releases/2021/atamyo-therapeutics-obtains-first-regulatory-authorization-in-europe-to-initiate-a-clinical-trial-for-ata-100-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2i-r9/
5. Atamyo Therapeutics reaches significant regulatory and financial milestones for ATA-100, its gene therapy to treat limb-girdle muscular dystrophy type 2I/R9. News Release. Atamyo Therapeutics. February 24, 2022. Accessed September 28, 2023. https://atamyo.com/press-releases/atamyo-therapeutics-reaches-significant-regulatory-and-financial-milestones-for-ata-100-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2i-r9/
6. Atamyo Therapeutics announces significant milestones for ATA-100 and ATA-200, its gene therapy programs to treat limb-girdle muscular dystrophy 2I/R9 and 2C/R5. News release. Atamyo Therapeutics. May16, 2022. Accessed September 7, 2023. https://atamyo.com/press-releases/atamyo-therapeutics-announces-significant-milestones-for-ata-100-and-ata-200-its-gene-therapy-programs-to-treat-limb-girdle-muscular-dystrophy-2i-r9-and-2c-r5/
7. Our Pipeline. Atamyo Therapeutics. Website. Accessed September 28, 2023. https://atamyo.com/science-technology/pipeline/
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025